The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer

Author(s): Wenwen Zhang, Zhaojun Shen, Hui Luo, Xiaoli Hu, Lihong Zheng, Xueqiong Zhu*.

Journal Name: Current Drug Targets

Volume 18 , Issue 10 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Ovarian cancer is the leading cause of deaths attributable to gynecologic malignancies. Late diagnosis and a high tendency of metastasis and drug resistance often lead to recurrence and poor outcomes. Anti-angiogenesis is considered a promising therapeutic strategy for recurrent ovarian cancers. Anti-VEGF body, bevacizumab, is an angiogenesis inhibitor with demonstrated activity and tolerable toxicity.

Objective: To elucidate the benefits and side effects of bevacizumab for the therapy of recurrent ovarian cancer.

Methods: Reviewed the results of published clinical trials.

Results: Recent Phase II studies indicated that bevacizumab monotherapy or in combination with conventional or other anti-angiogenic chemotherapy reagents could be effective for recurrent (platinum- sensitive and -resistant) ovarian cancers. Additionally, two phase III randomized trials reached similar conclusions that in either platinum-sensitive or -resistant ovarian cancers, adding bevacizumab to chemotherapy can improve progression-free survival. Despite the general recognition of bevacizumab as a well-tolerated drug in recurrent ovarian cancer patients, oncologists have become aware of the significant risks associated with gastrointestinal perforation.

Conclusion: Bevacizumab used alone or combined with other chemotherapy reagents is efficacious and tolerable in the treatment of recurrent ovarian cancer.

Keywords: Bevacizumab, chemotherapy, efficacy, ovarian cancer, recurrent, safety, chemotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 10
Year: 2017
Page: [1125 - 1131]
Pages: 7
DOI: 10.2174/1389450117666160502150237
Price: $58

Article Metrics

PDF: 52
HTML: 3